Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise - report from ACC2024

Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24: - Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 Kardia-2 Study - Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy - Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In APOC-3 And Triglycerides (TG) In Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results - Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial - Effect Of Gamification, Financial Incentives Or Both Combined To Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial Video: https://medicaldigest.org/scientific-contents/interview:late-breaking-clinical-trials-cholesterol-management-hypertension-and-exercise